BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, Hall J, Guino E, Peinado MA, Capella G. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954-1956. [PMID: 14647431 DOI: 10.1038/sj.onc.1207305] [Cited by in Crossref: 147] [Cited by in F6Publishing: 132] [Article Influence: 8.2] [Reference Citation Analysis]
Number Citing Articles
1 Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med 2022. [PMID: 35229974 DOI: 10.1111/jcmm.17228] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Montazeri-najafabady N, Dabbaghmanesh MH, Nasimi N, Sohrabi Z, Estedlal A, Asmarian N. Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms and their haplotypes in susceptibility to sarcopenia in Iranian older adults. BMC Geriatr 2022;22. [DOI: 10.1186/s12877-022-02765-6] [Reference Citation Analysis]
3 Akter R, Islam MS, Islam MS, Aziz MA, Hussain MS, Millat MS, Uddin MS, Islam MS. A case-control study investigating the association of TP53 rs1042522 and CDH1 rs16260 polymorphisms with prostate cancer risk. Meta Gene 2021;30:100962. [DOI: 10.1016/j.mgene.2021.100962] [Reference Citation Analysis]
4 Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, Nakagawara A, Tsunematsu Y. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1. Int J Clin Oncol 2021;26:2161-78. [PMID: 34633580 DOI: 10.1007/s10147-021-02011-w] [Reference Citation Analysis]
5 Shen CC, Cheng WY, Lee CH, Dai XJ, Chiao MT, Liang YJ, Hsieh WY, Mao TF, Lin GS, Chen SR, Liu BS, Chen JP. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 2020;20:709. [PMID: 32727419 DOI: 10.1186/s12885-020-07210-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sambyal V, Kaur S, Manjari M, Uppal MS, Singh NR, Sudan M, Guleria K. Linkage disequilibrium and haplotypes of five TP53 polymorphisms in oesophageal cancer patients. J Genet 2020;99. [DOI: 10.1007/s12041-020-01224-8] [Reference Citation Analysis]
7 Diakite B, Kassogue Y, Dolo G, Kassogue O, Keita ML, Joyce B, Neuschler E, Wang J, Musa J, Traore CB, Kamate B, Dembele E, Nadifi S, Isichei M, Holl JL, Murphy R, Doumbia S, Hou L, Maiga M. Association of PIN3 16-bp duplication polymorphism of TP53 with breast cancer risk in Mali and a meta-analysis. BMC Med Genet 2020;21:142. [PMID: 32620097 DOI: 10.1186/s12881-020-01072-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Orr BA, Clay MR, Pinto EM, Kesserwan C. An update on the central nervous system manifestations of Li-Fraumeni syndrome. Acta Neuropathol 2020;139:669-87. [PMID: 31468188 DOI: 10.1007/s00401-019-02055-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 16.5] [Reference Citation Analysis]
9 Elshazli RM, Toraih EA, Elgaml A, Kandil E, Fawzy MS. Genetic polymorphisms of TP53 (rs1042522) and MDM2 (rs2279744) and colorectal cancer risk: An updated meta-analysis based on 59 case-control studies. Gene 2020;734:144391. [PMID: 32001373 DOI: 10.1016/j.gene.2020.144391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
10 Dmytrzak A, Boroń A, Łoniewska B, Lewandowska K, Gorący I, Kaczmarczyk M, Ciechanowicz A. Two Functional TP53 Genetic Variants and Predisposition to Keloid Scarring in Caucasians. Dermatol Res Pract 2019;2019:6179063. [PMID: 31827503 DOI: 10.1155/2019/6179063] [Reference Citation Analysis]
11 Asai T, Tsuchiya Y, Mishra K, Behari A, Shukla P, Ikoma T, Kapoor VK, Nakamura K. Carcinogen Metabolism Pathway and Tumor Suppressor Gene Polymorphisms and Gallbladder Cancer Risk in North Indians: A Hospital-Based Case-Control Study. Asian Pac J Cancer Prev 2019;20:3643-7. [PMID: 31870105 DOI: 10.31557/APJCP.2019.20.12.3643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Zhang G, Xu Q, Liu J, Lv Z, Lu Y, Yang H, Sun L, Xing C, Yuan Y. Five P53 SNPs Involved in Low Rectal Cancer Risk and Prognosis in a Chinese Population. J Cancer 2019;10:1772-80. [PMID: 31205533 DOI: 10.7150/jca.26722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Hao W, Xu X, Shi H, Zhang C, Chen X. No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation. Eur J Med Res 2018;23:47. [PMID: 30309383 DOI: 10.1186/s40001-018-0345-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Taeubner J, Wieczorek D, Yasin L, Brozou T, Borkhardt A, Kuhlen M. Penetrance and Expressivity in Inherited Cancer Predisposing Syndromes. Trends Cancer 2018;4:718-28. [PMID: 30352675 DOI: 10.1016/j.trecan.2018.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
15 Elsaid A, Zahran R, Elshazli R, El-sayed A, Abou Samra M, El-tarapely F, Abdel-malak C. Genetic polymorphisms of TP53 Arg72Pro and Pro47Ser among Egyptian patients with colorectal carcinoma. Archives of Physiology and Biochemistry 2018;125:255-62. [DOI: 10.1080/13813455.2018.1453522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tian X, Dai S, Sun J, Jiang S, Jiang Y. The association between the TP53 Arg72Pro polymorphism and colorectal cancer: An updated meta-analysis based on 32 studies. Oncotarget 2017;8:1156-65. [PMID: 27901479 DOI: 10.18632/oncotarget.13589] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
17 Li N, Xie C, Lu NH. p53, a potential predictor of Helicobacter pylori infection-associated gastric carcinogenesis? Oncotarget 2016;7:66276-86. [PMID: 27556187 DOI: 10.18632/oncotarget.11414] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
18 Asadi M, Shanehbandi D, Zarintan A, Pedram N, Baradaran B, Zafari V, Shirmohamadi M, Hashemzadeh S. TP53 Gene Pro72Arg (rs1042522) Single Nucleotide Polymorphism as Not a Risk Factor for Colorectal Cancer in the Iranian Azari Population. Asian Pac J Cancer Prev 2017;18:3423-7. [PMID: 29286614 DOI: 10.22034/APJCP.2017.18.12.3423] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
19 Rivu SF, Apu MNH, Shabnaz S, Nahid NA, Islam MR, Al-mamun MMA, Nahar Z, Rabbi SNI, Ahmed MU, Islam MS, Hasnat A. Association of TP53 codon 72 and CDH1 genetic polymorphisms with colorectal cancer risk in Bangladeshi population. Cancer Epidemiology 2017;49:46-52. [DOI: 10.1016/j.canep.2017.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
20 Guha T, Malkin D. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. Cold Spring Harb Perspect Med 2017;7:a026187. [PMID: 28270529 DOI: 10.1101/cshperspect.a026187] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
21 Hashemi M, Amininia S, Ebrahimi M, Simforoosh N, Basiri A, Ziaee SAM, Narouie B, Sotoudeh M, Mollakouchekian MJ, Rezghi Maleki E. Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer. Oncol Lett. 2017;13:2483-2489. [PMID: 28454424 DOI: 10.3892/ol.2017.5739] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
22 Samuel N, Id Said B, Guha T, Novokmet A, Li W, Silwal-pandit L, Børrsen-dale A, Langerød A, Hudson TJ, Malkin D. Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk. Human Mutation 2017;38:265-8. [DOI: 10.1002/humu.23154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Kamiza AB, Hsieh LL, Tang R, Chien HT, Lai CH, Chiu LL, Lo TP, Hung KY, You JF, Wang WC, Hsiung CA, Yeh CC. TP53 Polymorphisms and Colorectal Cancer Risk in Patients with Lynch Syndrome in Taiwan: A Retrospective Cohort Study. PLoS One 2016;11:e0167354. [PMID: 27907203 DOI: 10.1371/journal.pone.0167354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Nagam SL, Katta S, Prasad VV. Gender specific association of TP53 polymorphisms (EX4 215G>C Arg72Pro, IVS3+40-41ins16, and IVS6+62G>A), with risk of oral cancer subtypes and overall survival of the patients. Mol Carcinog 2017;56:895-912. [PMID: 27532290 DOI: 10.1002/mc.22543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Vazharova R, Kremensky I. Individual capacity for DNA repair and maintenance of genomic integrity: a fertile ground for studies in the field of assisted reproduction. Biotechnology & Biotechnological Equipment 2016;30:419-33. [DOI: 10.1080/13102818.2016.1159923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wajnberg G, Passetti F. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery. Expert Opin Drug Discov 2016;11:257-68. [PMID: 26787005 DOI: 10.1517/17460441.2016.1143813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Tian C, Chen Z, Ma X, Yang M, Wang Z, Dong Y, Yang T, Yang W. Comparison of Genetic Variants in Cancer-Related Genes between Chinese Hui and Han Populations. PLoS One 2015;10:e0145170. [PMID: 26683024 DOI: 10.1371/journal.pone.0145170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
28 Zins K, Frech B, Taubenschuss E, Schneeberger C, Abraham D, Schreiber M. Association of the rs1346044 Polymorphism of the Werner Syndrome Gene RECQL2 with Increased Risk and Premature Onset of Breast Cancer. Int J Mol Sci 2015;16:29643-53. [PMID: 26690424 DOI: 10.3390/ijms161226192] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
29 Deben C, Deschoolmeester V, Lardon F, Rolfo C, Pauwels P. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Crit Rev Oncol Hematol 2016;99:63-73. [PMID: 26689115 DOI: 10.1016/j.critrevonc.2015.11.019] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 5.4] [Reference Citation Analysis]
30 Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA. The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome. Carcinogenesis 2016;37:81-6. [PMID: 26586794 DOI: 10.1093/carcin/bgv164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
31 Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V, Sivakumaran S, Gresham G, Cubitt L, Carvajal-Carmona L, Bertagnolli MM, Zauber AG, Tomlinson I, Farrington SM, Dunlop MG, Campbell H, Little J. Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas. Int J Epidemiol 2016;45:186-205. [PMID: 26451011 DOI: 10.1093/ije/dyv185] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
32 Puerta-García E, Cañadas-Garre M, Calleja-Hernández MÁ. Molecular biomarkers in colorectal carcinoma. Pharmacogenomics 2015;16:1189-222. [PMID: 26237292 DOI: 10.2217/PGS.15.63] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
33 Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P. Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. PLoS One 2015;10:e0134463. [PMID: 26226484 DOI: 10.1371/journal.pone.0134463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
34 Eskandari-Nasab E, Hashemi M, Amininia S, Ebrahimi M, Rezaei M, Hashemi SM. Effect of TP53 16-bp and β-TrCP 9-bp INS/DEL polymorphisms in relation to risk of breast cancer. Gene 2015;568:181-5. [PMID: 26003292 DOI: 10.1016/j.gene.2015.05.048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
35 Caminsky NG, Mucaki EJ, Rogan PK. Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis. F1000Res 2014;3:282. [DOI: 10.12688/f1000research.5654.2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kamihara J, Rana HQ, Garber JE. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 2014;35:654-62. [PMID: 24706533 DOI: 10.1002/humu.22559] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
37 Abderrahmane R, Louhibi L, Moghtit FZ, Boubekeur A, Benseddik K, Boudjema A, Benrrahal F, Aberkane M, Fodil M, Saidi-mehtar N. TP53 Arg 72Pro and MDM2 SNP309 Polymorphisms and Colorectal Cancer Risk: A West Algerian Population Study. Pathol Oncol Res 2015;21:629-35. [DOI: 10.1007/s12253-014-9867-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
38 Dehghan R, Hosseinpour Feizi MA, Pouladi N, Babaei E, Montazeri V, Fakhrjoo A, Sedaei A, Azarfam P, Nemati M. Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients. Pathol Oncol Res 2015;21:449-54. [PMID: 25410025 DOI: 10.1007/s12253-014-9846-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
39 Caminsky N, Mucaki EJ, Rogan PK. Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis. F1000Res 2014;3:282. [PMID: 25717368 DOI: 10.12688/f1000research.5654.1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 6.6] [Reference Citation Analysis]
40 Voropaeva EN, Voevoda MI, Pospelova TI, Maksimov VN. Linkage disequilibrium and haplotypes of the rs1042522, rs1625895, and rs1787862 markers of TP53 in patients with diffuse large B-cell lymphoma. Mol Biol 2014;48:664-70. [DOI: 10.1134/s0026893314050173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
41 Perriaud L, Marcel V, Sagne C, Favaudon V, Guédin A, De Rache A, Guetta C, Hamon F, Teulade-Fichou MP, Hainaut P, Mergny JL, Hall J. Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. Carcinogenesis 2014;35:2706-15. [PMID: 25269805 DOI: 10.1093/carcin/bgu206] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
42 Winiecka-Klimek M, Szybka M, Rieske P, Piaskowski S, Bienkowski M, Walczak M, Pacholczyk M, Rostkowski M, Zieba J, Banaszczyk M, Hulas-Bigoszewska K, Peciak J, Pawliczak R, Stoczynska-Fidelus E. PIN3 duplication may be partially responsible for TP53 haploinsufficiency. BMC Cancer 2014;14:669. [PMID: 25223755 DOI: 10.1186/1471-2407-14-669] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Marouf C, Tazzite A, Diakité B, Jouhadi H, Benider A, Nadifi S. Association of TP53 PIN3 polymorphism with breast cancer in Moroccan population. Tumour Biol 2014;35:12403-8. [PMID: 25201062 DOI: 10.1007/s13277-014-2556-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
44 Mahmood S, Sivoňová M, Matáková T, Dobrota D, Wsólová L, Dzian A, Mištuna D. Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Open Medicine 2014;9:405-16. [DOI: 10.2478/s11536-013-0300-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Heinze B, Herrmann LJM, Fassnacht M, Ronchi CL, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B, Hahner S. Less common genotype variants of TP53 polymorphisms are associated with poor outcome in adult patients with adrenocortical carcinoma. European Journal of Endocrinology 2014;170:707-17. [DOI: 10.1530/eje-13-0788] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
46 Laprano TD, Lemos EH, Cunha LM, Júnior JE, de SousaTeles RA, Rabenhorst SH. Association of TP53 codon 72 and intron 3 16-bp Ins/Del polymorphisms with cervical cancer risk. Tumour Biol 2014;35:7435-40. [PMID: 24782034 DOI: 10.1007/s13277-014-1988-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
47 Petkova R, Chelenkova P, Georgieva E, Chakarov S. What's Your Poison? Impact of Individual Repair Capacity on the Outcomes of Genotoxic Therapies in Cancer. Part I—Role of Individual Repair Capacity in the Constitution of Risk for Late-Onset Multifactorial Disease. Biotechnology & Biotechnological Equipment 2014;27:4208-16. [DOI: 10.5504/bbeq.2013.0097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Han SJ, O'Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update 2014;20:467-84. [PMID: 24634322 DOI: 10.1093/humupd/dmu002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 6.5] [Reference Citation Analysis]
49 Cintra HS, Pinezi JC, Machado GD, de Carvalho GM, Carvalho AT, dos Santos TE, Marciano RD, Soares Rde B. Investigation of genetic polymorphisms related to the outcome of radiotherapy for prostate cancer patients. Dis Markers 2013;35:701-10. [PMID: 24324286 DOI: 10.1155/2013/762685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
50 Singamsetty GK, Malempati S, Bhogadhi S, Kondreddy R, Govatati S, Tangudu NK, Govatati S, kuraganti AK, Bhanoori M, Kassetty K. TP53 alterations and colorectal cancer predisposition in south Indian population: A case-control study. Tumor Biol 2014;35:2303-11. [DOI: 10.1007/s13277-013-1305-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
51 Andrade R, Cardoso L, Ferman S, Faria P, Seuánez H, Achatz M, Vargas F. Association of TP53 polymorphisms on the risk of Wilms tumor: TP53 Polymorphisms on Risk of Wilms Tumor. Pediatr Blood Cancer 2014;61:436-41. [DOI: 10.1002/pbc.24775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ortiz-Cuaran S, Cox D, Villar S, Friesen MD, Durand G, Chabrier A, Khuhaprema T, Sangrajrang S, Ognjanovic S, Groopman JD, Hainaut P, Le Calvez-Kelm F. Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma. Genes Chromosomes Cancer 2013;52:912-9. [PMID: 23836507 DOI: 10.1002/gcc.22086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
53 Wu D, Zhang Z, Chu H, Xu M, Xue Y, Zhu H, Zhang Z. Intron 3 sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: evidence from meta-analysis. PLoS One 2013;8:e61662. [PMID: 23620777 DOI: 10.1371/journal.pone.0061662] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
54 Brasil-Costa I, Alencar DO, Raiol-Moraes M, Pessoa IA, Brito AW, Jati SR, Santos SE, Burbano RM, Ribeiro-dos-Santos AK. Molecular characterization of TP53 gene in human populations exposed to low-dose ionizing radiation. Biomed Res Int 2013;2013:303486. [PMID: 23586029 DOI: 10.1155/2013/303486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Pellicciotta I, Yang CP, Venditti CA, Goldberg GL, Shahabi S. Response to microtubule-interacting agents in primary epithelial ovarian cancer cells. Cancer Cell Int 2013;13:33. [PMID: 23574945 DOI: 10.1186/1475-2867-13-33] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
56 Lajin B, Alhaj Sakur A, Alachkar A. Association between polymorphisms in apoptotic genes and susceptibility for developing breast cancer in Syrian women. Breast Cancer Res Treat 2013;138:611-9. [PMID: 23468244 DOI: 10.1007/s10549-013-2467-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
57 Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death Dis 2013;4:e492. [PMID: 23412385 DOI: 10.1038/cddis.2013.24] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
58 Paskulin DD, Cunha-Filho JS, Souza CA, Bortolini MC, Hainaut P, Ashton-Prolla P. TP53 PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure. Cell Death Dis 2012;3:e392. [PMID: 23013791 DOI: 10.1038/cddis.2012.116] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
59 Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, Vodicka P. Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. Mutagenesis 2012;27:211-8. [PMID: 22294769 DOI: 10.1093/mutage/ger067] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
60 Gomes MC, Kotsopoulos J, de Almeida GL, Costa MM, Vieira R, Filho Fde A, Pitombo MB, F Leal PR, Royer R, Zhang P, Narod SA. The R337H mutation in TP53 and breast cancer in Brazil. Hered Cancer Clin Pract 2012;10:3. [PMID: 22455664 DOI: 10.1186/1897-4287-10-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
61 Hadj Salem I, Kamoun F, Louhichi N, Trigui M, Triki C, Fakhfakh F. Impact of single-nucleotide polymorphisms at the TP53-binding and responsive promoter region of BCL2 gene in modulating the phenotypic variability of LGMD2C patients. Mol Biol Rep 2012;39:7479-86. [PMID: 22367371 DOI: 10.1007/s11033-012-1581-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
62 Gallegos-Arreola MP, Valencia-Rodríguez LE, Puebla-Pérez AM, Figuera LE, Zúñiga-González GM. The TP53 16-bp duplication polymorphism is enriched in endometriosis patients. Gynecol Obstet Invest 2012;73:118-23. [PMID: 22353881 DOI: 10.1159/000330702] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
63 Mittal RD, George GP, Mishra J, Mittal T, Kapoor R. Role of functional polymorphisms of P53 and P73 genes with the risk of prostate cancer in a case-control study from Northern India. Arch Med Res 2011;42:122-7. [PMID: 21565625 DOI: 10.1016/j.arcmed.2011.03.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
64 Wu M, Wu RT, Wang TT, Cheng WH. Role for p53 in selenium-induced senescence. J Agric Food Chem 2011;59:11882-7. [PMID: 21973212 DOI: 10.1021/jf203012a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
65 Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 2012;351:101-10. [PMID: 21930187 DOI: 10.1016/j.mce.2011.09.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]
66 Saunders IW, Ross J, Macrae F, Young GP, Blanco I, Brohede J, Brown G, Brookes D, Lockett T, Molloy PL, Moreno V, Capella G, Hannan GN. Evidence of linkage to chromosomes 10p15.3-p15.1, 14q24.3-q31.1 and 9q33.3-q34.3 in non-syndromic colorectal cancer families. Eur J Hum Genet 2012;20:91-6. [PMID: 21829229 DOI: 10.1038/ejhg.2011.149] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
67 Denisov EV, Sukhanovskaya TV, Dultseva TS, Malinovskaya EA, Litviakov NV, Slonimskaya EM, Choinzonov EL, Cherdyntseva NV. Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations. Genet Test Mol Biomarkers 2011;15:901-7. [PMID: 21810023 DOI: 10.1089/gtmb.2011.0038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
68 Liu L, Wang K, Zhu ZM, Shao JH. Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch Med Res 2011;42:60-9. [PMID: 21376265 DOI: 10.1016/j.arcmed.2011.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
69 Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Hum Genet 2011;130:789-94. [PMID: 21688173 DOI: 10.1007/s00439-011-1039-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
70 Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol 2011;12:477-88. [PMID: 21514219 DOI: 10.1016/S1470-2045(11)70076-6] [Cited by in Crossref: 186] [Cited by in F6Publishing: 115] [Article Influence: 16.9] [Reference Citation Analysis]
71 Song HR, Kweon SS, Kim HN, Piao JM, Yun WJ, Choi JS, Hwang JE, Yoon JY, Kim HR, Park YK. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer. 2011;14:242-248. [PMID: 21461655 DOI: 10.1007/s10120-011-0034-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
72 Rizzato C, Scherer D, Rudnai P, Gurzau E, Koppova K, Hemminki K, Canzian F, Kumar R, Campa D. POMC and TP53 genetic variability and risk of basal cell carcinoma of skin: Interaction between host and genetic factors. J Dermatol Sci 2011;63:47-54. [PMID: 21536413 DOI: 10.1016/j.jdermsci.2011.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
73 Bišof V, Salihović MP, Narančić NS, Skarić-Jurić T, Jakić-Razumović J, Janićijević B, Rudan P. The TP53 gene polymorphisms and survival of sporadic breast cancer patients. Med Oncol 2012;29:472-8. [PMID: 21365326 DOI: 10.1007/s12032-011-9875-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
74 Phang BH, Chua HW, Li H, Linn YC, Sabapathy K. Characterization of novel and uncharacterized p53 SNPs in the Chinese population--intron 2 SNP co-segregates with the common codon 72 polymorphism. PLoS One 2011;6:e15320. [PMID: 21249215 DOI: 10.1371/journal.pone.0015320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
75 Wang JJ, Zheng Y, Sun L, Wang L, Yu PB, Dong JH, Zhang L, Xu J, Shi W, Ren YC. TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol Biol Rep 2011;38:4847-53. [PMID: 21140221 DOI: 10.1007/s11033-010-0619-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
76 Marcel V, Tran PL, Sagne C, Martel-planche G, Vaslin L, Teulade-fichou M, Hall J, Mergny J, Hainaut P, Van Dyck E. G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis 2011;32:271-8. [DOI: 10.1093/carcin/bgq253] [Cited by in Crossref: 144] [Cited by in F6Publishing: 144] [Article Influence: 12.0] [Reference Citation Analysis]
77 Joshi AM, Budhathoki S, Ohnaka K, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol. 2011;41:232-238. [PMID: 21051533 DOI: 10.1093/jjco/hyq200] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
78 Sayagués JM, Fontanillo C, Abad Mdel M, González-González M, Sarasquete ME, Chillon Mdel C, Garcia E, Bengoechea O, Fonseca E, Gonzalez-Diaz M, De las Rivas J, Muñoz-Bellvis L, Orfao A. Mapping of genetic abnormalities of primary tumours from metastatic CRC by high-resolution SNP arrays. PLoS One 2010;5:e13752. [PMID: 21060790 DOI: 10.1371/journal.pone.0013752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
79 Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008. [PMID: 20182602 DOI: 10.1101/cshperspect.a001008] [Cited by in Crossref: 847] [Cited by in F6Publishing: 839] [Article Influence: 70.6] [Reference Citation Analysis]
80 Bellini I, Pitto L, Marini MG, Porcu L, Moi P, Garritano S, Boldrini L, Rainaldi G, Fontanini G, Chiarugi M, Barale R, Gemignani F, Landi S. DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum Mutat 2010;31:456-65. [PMID: 20127977 DOI: 10.1002/humu.21214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
81 Malisic EJ, Jankovic RN, Radulovic SS. An intronic variant in the TP53 gene in Serbian women with cervical or ovarian cancer. Cancer Genet Cytogenet 2010;198:173-5. [PMID: 20362235 DOI: 10.1016/j.cancergencyto.2010.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
82 Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36:431-438. [PMID: 20363586 DOI: 10.1016/j.ejso.2010.03.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
83 Eren F, Akkiprik M, Atuğ O, Sönmez O, Tahan G, Ozdemir F, Hamzaoğlu HO, Celikel CA, Imeryüz N, Avşar E, Ozer A. R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. Pathol Oncol Res 2010;16:563-8. [PMID: 20309662 DOI: 10.1007/s12253-010-9255-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
84 Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, Gargouri A, Mokdad-Gargouri R. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 2010;34:184-8. [PMID: 20233677 DOI: 10.1016/j.canep.2010.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
85 Souček K, Gajdušková P, Brázdová M, Hýžd'alová M, Kočí L, Vydra D, Trojanec R, Pernicová Z, Lentvorská L, Hajdúch M, Hofmanová J, Kozubík A. Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genetics and Cytogenetics 2010;197:107-16. [DOI: 10.1016/j.cancergencyto.2009.11.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
86 Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol 2010;22:64-9. [PMID: 19952748 DOI: 10.1097/CCO.0b013e328333bf00] [Cited by in Crossref: 79] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
87 Naccarati A, Pardini B, Polakova V, Smerhovsky Z, Vodickova L, Soucek P, Vrana D, Holcatova I, Ryska M, Vodicka P. Genotype and haplotype analysis of TP53 gene and the risk of pancreatic cancer: an association study in the Czech Republic. Carcinogenesis 2010;31:666-70. [PMID: 20110284 DOI: 10.1093/carcin/bgq032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
88 Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, Su L. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31:643-647. [PMID: 20089604 DOI: 10.1093/carcin/bgq018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
89 Hu Z, Li X, Yuan R, Ring BZ, Su L. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 2010;120:705-14. [DOI: 10.1007/s10549-009-0488-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
90 Martinez R, Rohde V, Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2010;96:321-9. [PMID: 19644652 DOI: 10.1007/s11060-009-9967-4] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
91 Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet. 2009;17:1658-1667. [PMID: 19536170 DOI: 10.1038/ejhg.2009.102] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
92 Hall J, Marcel V, Bolin C, Fernet M, Tartier L, Vaslin L, Hainaut P. The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype–phenotype correlations. Biochemical Society Transactions 2009;37:527-33. [DOI: 10.1042/bst0370527] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
93 Polakova V, Pardini B, Naccarati A, Landi S, Slyskova J, Novotny J, Vodickova L, Bermejo JL, Hanova M, Smerhovsky Z, Tulupova E, Kumar R, Hemminki K, Vodicka P. Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum Mutat 2009;30:661-8. [DOI: 10.1002/humu.20931] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
94 Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107. [PMID: 19165225 DOI: 10.1038/nrc2584] [Cited by in Crossref: 427] [Cited by in F6Publishing: 412] [Article Influence: 32.8] [Reference Citation Analysis]
95 Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, Demirkalem P, Abacioglu U, Sengoz M, Sav A, Ozer A. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Pathol Oncol Res 2009;15:359-68. [DOI: 10.1007/s12253-008-9129-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
96 Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008;8:357. [PMID: 19046423 DOI: 10.1186/1471-2407-8-357] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 3.5] [Reference Citation Analysis]
97 Pangilinan F, Geiler K, Dolle J, Troendle J, Swanson DA, Molloy AM, Sutton M, Conley M, Kirke PN, Scott JM, Mills JL, Brody LC. Construction of a high resolution linkage disequilibrium map to evaluate common genetic variation in TP53 and neural tube defect risk in an Irish population. Am J Med Genet A 2008;146A:2617-25. [PMID: 18798306 DOI: 10.1002/ajmg.a.32504] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
98 Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF, Zhu G. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007;37:385-390. [PMID: 17599946 DOI: 10.1093/jjco/hym034] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
99 Mammano E, Belluco C, Bonafé M, Olivieri F, Mugianesi E, Barbi C, Mishto M, Cosci M, Franceschi C, Lise M, Nitti D. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 2009;35:415-9. [PMID: 18468835 DOI: 10.1016/j.ejso.2008.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
100 Boldrini L, Gisfredi S, Ursino S, Lucchi M, Greco G, Mussi A, Donati V, Fontanini G. Effect of the p53 codon 72 and intron 3 polymorphisms on non-small cell lung cancer (NSCLC) prognosis. Cancer Invest 2008;26:168-72. [PMID: 18259947 DOI: 10.1080/07357900701788023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
101 Woelfelschneider A, Popanda O, Lilla C, Linseisen J, Mayer C, Celebi O, Debus J, Bartsch H, Chang-Claude J, Schmezer P. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis 2008;29:1758-64. [PMID: 18332046 DOI: 10.1093/carcin/bgn067] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
102 Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008;8:32. [PMID: 18230179 DOI: 10.1186/1471-2407-8-32] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 5.1] [Reference Citation Analysis]
103 Lavelle C, Salles B, Wiesmüller L. DNA repair, damage signaling and carcinogenesis. DNA Repair (Amst) 2008;7:670-80. [PMID: 18221920 DOI: 10.1016/j.dnarep.2007.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
104 Zambetti GP. The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 2007;213:370-3. [PMID: 17671971 DOI: 10.1002/jcp.21217] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.1] [Reference Citation Analysis]
105 Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008;261:21-5. [PMID: 18248785 DOI: 10.1016/j.canlet.2007.10.044] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 5.0] [Reference Citation Analysis]
106 Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008;112:2467-74. [DOI: 10.1002/cncr.23472] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
107 Khrunin A, Verbenko D, Nikitina K, Limborska S. Regional differences in the genetic variability of Finno-Ugric speaking Komi populations. Am J Hum Biol 2007;19:741-50. [DOI: 10.1002/ajhb.20620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
108 Grunhage F, Jungck M, Lamberti C, Berg C, Becker U, Schulte-Witte H, Plassmann D, Rahner N, Aretz S, Friedrichs N. Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis. 2008;23:147-154. [PMID: 17960397 DOI: 10.1007/s00384-007-0388-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
109 Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics 2007;17:639-45. [PMID: 17622940 DOI: 10.1097/FPC.0b013e3280d5121c] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
110 Roman S, Pétré A, Thépot A, Hautefeuille A, Scoazec JY, Mion F, Hainaut P. Downregulation of p63 upon exposure to bile salts and acid in normal and cancer esophageal cells in culture. Am J Physiol Gastrointest Liver Physiol 2007;293:G45-53. [PMID: 17615180 DOI: 10.1152/ajpgi.00583.2006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
111 Kashkin KN, Khlgatian SV, Gurova OV, Kuprash DV, Nedospasov SA. New mutations in the human p53 gene--a regulator of the cell cycle and carcinogenesis. Biochemistry (Mosc) 2007;72:282-92. [PMID: 17447881 DOI: 10.1134/s0006297907030054] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
112 Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM. Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures, and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 2008;108:93-9. [PMID: 17624591 DOI: 10.1007/s10549-007-9573-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
113 Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007;26:2157-65. [PMID: 17401424 DOI: 10.1038/sj.onc.1210302] [Cited by in Crossref: 563] [Cited by in F6Publishing: 565] [Article Influence: 37.5] [Reference Citation Analysis]
114 Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V, Ciferri E, Percivale P, Bianchi Scarrà G, Nasti S, Fronza G, Varesco L. Increased Risk of Colorectal Adenomas in Italian Subjects Carrying the <i>p53</i> PIN3 A2-Pro72 Haplotype. Digestion 2007;74:228-35. [DOI: 10.1159/000100966] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
115 Vietri MT, Molinari AM, Iannella I, Cioffi M, Bontempo P, Ardovino M, Scaffa C, Colacurci N, Cobellis L. Arg72Pro p53 polymorphism in Italian women: no association with endometriosis. Fertil Steril 2007;88:1468-9. [PMID: 17412337 DOI: 10.1016/j.fertnstert.2006.12.049] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
116 Naccarati A, Pardini B, Hemminki K, Vodicka P. Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res. 2007;635:118-145. [PMID: 17419091 DOI: 10.1016/j.mrrev.2007.02.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 3.9] [Reference Citation Analysis]
117 Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detection and Prevention 2007;31:207-13. [DOI: 10.1016/j.cdp.2007.04.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
118 Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL, Hunter DJ. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer. 2006;119:1863-1868. [PMID: 16721787 DOI: 10.1002/ijc.22057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
119 Ahmed FE. Gene-gene, gene-environment & multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2006;24:1-101. [PMID: 16690537 DOI: 10.1080/10590500600614295] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
120 De Chaudhuri S, Mahata J, Das JK, Mukherjee A, Ghosh P, Sau TJ, Mondal L, Basu S, Giri AK, Roychoudhury S. Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat Res 2006;601:102-12. [PMID: 16930632 DOI: 10.1016/j.mrfmmm.2006.06.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
121 Gu J, Wu X, Dong Q, Romeo MJ, Lin X, Gutkind JS, Berman DM. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. Cancer 2006;106:2716-24. [PMID: 16691626 DOI: 10.1002/cncr.21944] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
122 Lima JM, Serafim PV, Silva ID, Forones NM. [Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer]. Arq Gastroenterol 2006;43:8-13. [PMID: 16699611 DOI: 10.1590/s0004-28032006000100005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
123 Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006;25:1602-11. [DOI: 10.1038/sj.onc.1209367] [Cited by in Crossref: 151] [Cited by in F6Publishing: 141] [Article Influence: 9.4] [Reference Citation Analysis]
124 Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9): 1426-1429 [PMID: 16552814 DOI: 10.3748/wjg.v12.i9.1426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
125 Tan XL, Popanda O, Ambrosone CB, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Chang-Claude J. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 2006;97:255-62. [PMID: 16331344 DOI: 10.1007/s10549-005-9119-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
126 Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, Chen W, Jin G, Liu J, Gao J, Wang X, Wei Q, Shen H. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006;27:766-71. [DOI: 10.1093/carcin/bgi295] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
127 Kamiya Y, Ohshima T. The Individual Cell Properties of Oral Squamous Cell Carcinoma and p53 Tumor Suppressor Gene Mutation. Oral Science International 2005;2:104-17. [DOI: 10.1016/s1348-8643(05)80013-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
128 Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer 2005;5:105. [PMID: 16109171 DOI: 10.1186/1471-2407-5-105] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
129 Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, Liou SH, Chang JT, Cheng AJ. p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan. Br J Cancer 2005;92:30-5. [PMID: 15583690 DOI: 10.1038/sj.bjc.6602271] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
130 Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol 2005; 11(3): 331-335 [PMID: 15637738 DOI: 10.3748/wjg.v11.i3.331] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.2] [Reference Citation Analysis]
131 Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, Panda CK, Roychoudhury S. Risk assessment ofp53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern india. Int J Cancer 2005;117:786-93. [DOI: 10.1002/ijc.21263] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
132 Kashkin KN, Strizhkov BN, Gryadunov DA, Surzhikov SA, Grechishnikova IV, Kreindlin EY, Chupeeva VV, Evseev KB, Turygin AY, Mirzabekov AD. Detection of single-nucleotide polymorphisms in the p53 gene by LDR/RCA in hydrogel microarrays. Mol Biol 2005;39:26-34. [DOI: 10.1007/s11008-005-0004-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]